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*P < 0.05, **P < 0.01 d. to baseline, @P < 005 Group 1vs. Group 2
Group 2 pts had depressed microvascular and ECA dilation with ACH com-
pared to Group 1 pts (Table). In contrast, with SP, microvascular dilation was
similar in both groups, and ECA dilation was higher in those without RF; how-
ever, the correlation between the magnitude of ECA dilation with ACH and
SP was weak (r = 0.21). Thus, there is a preponderance of muscarinic recep-
tors in the microvessels, whereas SP receptors are located predominantly in
human ECA. In pts with RF and atherosclerosis, ACH-induced endothelium-
dependent ECA and microvascular dilation is depressed, but microvascu-
lar dilation with SP appears unaffected and SP-induced ECA dilation is only
mildly reduced. Therefore, atherosclerosis and its RF appearto produce non-
uniform dysfunction of various endothelial cell surface receptors in the hu-
man coronary vasculature.
Effects of NPC 15669 on Myocardial Stunning
and Infarction Size
Victor L. Serebruany, Matthew L. Schlossberg, Paul A. Gurbel, Robert A. Vogel,
William R. Herzog. University ofMaryland, Baltimore, MD
impaired (I = ejection fraction <40%) LV-function, 17 pts in Nand 7 pts in I
received atropine before ischemia was induced by incremental atrial pacing.
Placebo was administered to a matching control group (CN and CI, resp.). All
pts had>70% left CAD. During maximal pacing, heart rate and rate pressure
product (myocardial oxygen demand) where 7% and 12% higher in N, com-
pared to CN, but were comparable in I and CI. Moreover, 1 minute post pac-
ing these values were 8% and 12% higher, resp., N vs CN. Vasoconstrictive
circulating neurohormones (norepinephrine) increased similarly in all groups.
Coronary flow increased 23% more in N than in CN and to a similar extent
in I and CI. Myocardial ischemia, as indicated by changes in myocardiallac-
tate metabolism, was less in N [lactate extraction +10% (N) vs -21 % (CN),
-18% (I) and -19% (CI)]. Fifteen minutes after pacing, coronary flow was
still decreased by 11 % and coronary vascular resistance increased by 15%
in CN, as compared to N. Thus, reduction of parasympathetic tone improves
coronary flow and reduces myocardial ischemia in the latter, despite similar
sympathetic activation and more pronounced myocardial oxygen demand in
N. This supports a greater role for cardiovascular parasympathetic control of
(diseasedl coronary arterial system in normal LV-function and, possibly, a new
area of intervention in anti ischemic therapy in the latter.
Correlation Between Magnesium Deficiency and
Disease ActiVity in Patients with Variant Angina
and the Effect of Oral Magnesium
Supplementation
Kazuo Satake, Jong-Dae Lee, Hiromasa Shimizu, Hiroyasu Uzui, Norio Kawasaki,
Akiyosi Tsubokawa, Taeko Sugiyama, Takanori Ueda, Toru Nakamura. The First
Department of Internal Medicine, Fukui Medical School, Fukui, Japan
Purpose; We examined whether or not the degree of intracellular magnesium
(Mg) deficiency correlates with disease activity of variant angina (VA) and the
effect of oral Mg supplementation. Methods; Eighteen patients with VA (17
men and a woman) were divided into 2 groups according to the frequency of
occurrence of angina attacks (inactive and active group> 3 angina attacks
per week).
We measured Mg status by serum, urinary excretion, 24-hour Mg reten-
tion rate. Intracellular Mg content of mononuclear cell (MNC) and erythrocyte
were also measured by atomic absorption spectrophotometry We also ex-
amined the effect of oral Mg supplementation (Mg oxide 0.6 g/day, more
than 2 months) to refractory patients (n = 4) with Mg deficiency. Result; There
were no significant differences in serum Mg content between active and in-
active groups. Urinary Mg excretion in a day in active group (136.4 ± 36.6
mg/dat) was significantly higher than in inactive group (59.1 ± 7.0; P < 0.05).
Retention rate and intracellular Mg content of MNC and erythrocyte were
57.0 ± 7.3 vs 24.7 ± 3.2% (p < 0.01), 151.3 ± 14.4 vs 214.3 ± 8.0 fg/cell (p <
0.01) and 3.8 ± 0.5 vS 5.1 ± 0.4 fg/cell (p < 0.05). respectively. Retention rate
and intracellular Mg content of MNC and erythrocyte correlated well with the
frequency of angina attacks in these patients (r = 0.78, p < 0.01: r = 0.76, P
< 0.01 : r = -0.50, p < 0.05). With oral Mg supplementation, the response to
calcium antagonist was improved, coupled with the increase of intracellular
Mg content, from 151 ± 19.8 to 226.8 ± 17.0 fglcell in MNC and from 3.0 ±
0.6 to 5.0 ± 0.3 fg/cell in erythrocyte.
Conclusion; It is concluded that the degree of intracellular Mg deficiency
correlates well with disease activity of VA, suggesting that Mg deficiency
plays an important role in accelerating disease activity. Oral Mg supplemen-
tation appears to be an effective and less expensive regimen for patients with
VA.
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Does the Abnormal Endothelial Response of the
Human Coronary Vasculature in Atherosclerosis
Extend Beyond the Muscarinic Receptor?
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Arshed A. Quyyumi, David Mulcahy, Syed S. Husain, Neil P. Andrews, Gregory
B. Johnson, Rita Mincemoyer. Julio A. Panza, Richard O. Cannon III. National
InsMutes ofHealth, Bethesda, MD
To investigate whether atherosclerosis and its risk factors (RF) that are known
to result in abnormal coronary vasodilator responses to muscarinic receptor
stimulation with acetylcholine{ACH), are also associated with generalized en-
dothelial receptor dysfunction, we compared the effects of substance P(SP)
with those of ACH in the human coronary vasculature. In 25 patients, 7 (Group
1) with normal coronary arteries and no RF. and 18 (Group 2) with either RF
for, orestablished atherosclerosis (>20% stenosis), intracoronaryACH (3, 30,
100, 300 fLg/min) and SP (5, 10, 20 pmollmin) were given. Coronary blood
flow was measured using a Doppler flow wire and epicardial coronary artery
(ECA) diameter by quantitative angiography. Results; Microvascular dilation
measured as a decrease in coronary vascular resistance (CVR) with ACH was
greater compared to SP (-49 ± 23% vs. -24 ± 19% respectively, p < 0.01),
but ECA dilation with SP was greater compared to ACH (0 ± 14% (ACH) vs.
16±17%SP,p<0.01).
istered to determine the influence of ISO on endothelial dependent and inde-
pendent vasodilatation. In the control state (*p < 0.05). both IC-ACh and IC-
SNP resulted in marked coronary vasodilatation (ll. CBF ACh 76 ± 6* mllmin
and SNP 37 ± 7*) while IC-ANP did not alter CBF. IC-ISO increased basal
CBF (52 ± 11 ml/min to 87 ± 21*) and LV contractility (+dP/dt 1803 ± 93
mmHgL/sec to 2395 ± 151*). and decreased coronary vascular resistance
(CVR 2.6 ± 0.3 RU to 1.4 ± 0.2*) and coronary perfusion pressure (105 ±
7 mmHg to 87 ± 7*). In the presence of ISO, IC-ANP significantly increased
CBF (87 ± 21 ml/min to 117 ± 26*) while ACh and SNP-mediated coronary
vasodilation were similar to control changes.
In summary, IC-ISO augments ANP-mediated coronary vasodilatation but
does not enhance ACh or SNP mediated vasodilatation. This observation
suggests a functional link between the natriuretic peptide system and the
II-adrenergic system in the control of CBF. The elevation in circulating cat-
echolamines observed in CH F may, therefore, serve in part to augment en-
dogenous ANP-mediated coronary vasodilation and thus be coronary protec-
tive in the progression of CHF.
1930-1071
Anti-Ischemic Agents and Mechanisms
Ad FM. van den Heuvel, Martin van der Ent, Willem J. Remme. Sticares Foundation,
Rotterdam, The Netherlands
Cardiovascular parasympathetic control reportedly is reduced in left ventricu-
lar (LV) dysfunction and in heart-failure. To evaluate whether parasympathetic
intervention differentially affects coronary flow and ischemia in normal (N) vs
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Leukocytes have been implicated in myocardial infarction (MI) development
and progression. We tested the efficacy of the novel leukocyte recruitment in-
hibitor NPC 15669 (Scios Nova, Inc.) on myocardial stunning (MS) and precon-
ditioned MI. NPC is a member of the leumedins, and is an inhibitor of leuko-
cyte adhesion to endothelium via blockage of integrin binding. We also show,
that NPC 15669 have strong antiplatelet effects. In an open chested swine
model, NPC 15669 (10 mg NPC/kg loading dose followed by constant infu-
sion at 6 mg/kg-1/h-l )was administered in 6 animals. Myocardial thickening
(MT) was determined by epicardial ultrasound. The left anterior descending
artery was occluded for 8 min. followed by 90 min. of reperfusion, during
which myocardial MT was recorded at regular intervals. We have found that
treatment with NPC 15669 increases myocardial contractility and significantly
decreases MS time compared to six controls (26.7 ± 4.0 min vs. 50.0 ± 4.3
min, p = 0.0026). This report also demonstrates the beneficial effects of NPC
15669 on myocardial tissue survival after a period of ischemia. In NPC 15669
treated animals 23.4 ± 6.7% of at risk tissue became necrotic compared to
53.0 ± 6.6% in controls, p = 0.0102. Our data suggests that NPC 15669 sig-
nificantly reduces myocardial injury in both the stunning and infarction mod-
Parasympathetic Intervention Affects Ischemia
by Increasing Coronary Flow in Normal, but not
in Impaired Left Ventricular Function. A New
Approach to Antilschemic Therapy?
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els. The precise mechanism of these effects is unknown, but may be related
to the inhibition of platelet function and/or leukocyte recruitment.
Robert J. Anders, John C. Alexander, Gary L. Hantsbarger, Dan M. Burns, Stuart
D. Oliver, Graham Cole, Desmond J. Fitzgerald. Searle Pharm., Skokie, IL; Besse/aar
Associates, Leeds, UK; Royal College of Surgeon, Dublin, Ireland
1931-1111 Platelet Activation and Aggregation by
Therapeutic Doses of Heparin
1931-1131 Demonstration of Potent Inhibition of Platelet
Aggregation with an Orally Active GPllb/IIIA
Receptor Antagonist
Zihui Xiao, Pierre Theroux, John R. Plachetka. Montreal Heart Institute, Montreal,
Quebec, Canada
Thus, heparin, but not argatroban, a direct thrombin inhibitor, induced P-
selectin expression and GP lib/lila activation in the basal state and following
agonist stimulation at low concentrations.
Control
Basal 1.80 ± 0.67 0.66 ± 0.114 0.011 ± 0.0024
ADP 701 ± 15.99 3.5 ± 1,48 101 ± 4.13 018±0074 43 ± 2.25
TRP 18.8 ± 16,45 081 ± 0.61 2.77 ± 2.02 0.05 ± 0.039 2.2 ± 1.84
Heparin
Basal 3.60 ± 1,42* 1.00 ± 0.292* 0.018 ± 0.0047 t
ADP 76.6 ± 12,49* 4.2 ± 1.70* 13.2 ± 4,43* 0.24 ± 0.087* 88 ± 3.06t
TRP 32.9 ± 25.60* 1.5 ± 1.17* 3.32 ± 2.24* 0.06 ± 0.039 6.2 ± 1.84*
D, x =PBO
10 all others=50 mg dose
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This single-blind, placebo-controlled study evaluated the tolerability and
pharmacodynamic (PO) response of the first dose of the oral GPlib/llia re-
ceptor antagonist, SC-54684A (ethyl 3S-[[4-[[4(amino-iminomethyl)phenyl]a-
mino]-l,4-dioxobutyl]amino]-4-pentynoate, monohydrochloride). SC-54684A
(SC) is the pro-drug of the active compound, SC-54701A. Six healthy male
subjects received 50 mg of SC (free base) and 2 received placebo (PBO). Re-
sults of the inhibition to AOP (20 I'M) induced platelet aggregation are shown
below:
100
Effects of Inhibition of Nitric Oxide Synthesis in
Proximal and Distal Segments in Patients with
Normal Arteries and in Patients with Coronary
Artery Disease
Dimltris Tousoulis, Tom Crake, Costas Tentolouris, David C. Lefroy, John Gialafos,
Pavlos Toutouzas, Graham Davies. Cardiology Units, Athens University Medical
School, Greece; Hammersmith Hospital, London. UK
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Bleeding time increased a mean of 5.6 fold at 4 hrs post-dose and returned
to within normal limits at 8 hrs after dosing. No significant changes in lab
values or bleeding complications occurred. Peak serum concentrations co-
incided with peak PO effects of inhibition of platelet aggregation.
Conclusion; SC-54684A has a rapid onset of potent inhibition of platelet
aggregation that is sustained for up to 10 hours after dosing.
1931-11412.3 ± 2.07*2.0 ± 2.61
Max%BIPL%BI
2.30 ± 0.75 0.82 ± 0.192* 0.015 ± 00041*
691 ± 1962 3.5± 1.75 11.4±4,42 0.21 ±0.085
21.0 ± 14.23 0.88 ± 0.56 2.48 ± 1.12 0.05 ± 0.021
PAC-1
PL%
*p < 0.05 and t p < 001 vs Control
Argatroban
Basal
ADP
TRP
To understand better the complex interaction of heparin with platelets,
this study investigated platelet function by flow cytometry and aggregation
curves, with and without the drug, in 7 pts with unstable angina and 7 normal
individuals. Method and Results: Platelet aggregation induced by low doses
AOP (0.3125 /LM) and thrombin receptor agonist peptide (TRAP 0.625 I'M)
was quantified in platelet-rich plasma (PRP) before and after the administra-
tion of intravenous heparin at doses prolonging the aPTI 2.5 x control and
also after the addition in whole blood, ex vivo of therapeutic concentration of
heparin (0.2 U/mlj, argatroban (1 ng/ml) or of an equal volume of normal saline
(Control). Platelet activation was evaluated by the percentage of fluorescein
positive platelets (PL%) and the binding index per platelet (BI), using antibod-
ies directed against P-selectin (C062) and activated GP lib/lila receptor (pAC-
1). Following intravenous heparin, the maximal shift in platelet aggregation
(Max%) increased from 6.3 ± 3.6 to 11.6 ± 8.5 with AOP and from 4.4 ± 3.0
to 11.9 ± 5.2 (p < 0.05) with TRAP. The results of the ex vivo studies (x ± SO)
were:
PRP optical aggregation (%) Before AfterASA
1 h. 24 h
ADP (5/LM): L-ASA 73 ± 21 50 ± 14* 45± 15*
H-ASA 65 ± 23 54 ± 17* 52 ± 16*
PI 69 ± 18 72 ± 22 69 ± 14
Col (3 /Lg/ml): L-ASA 64 ± 19 33 ± 13* 36 ± 18*
H-ASA 60± 16 32 ± 17* 34 ± 14*
PI 55 ± 13 56 ± 18 57 ± 14
Rosa-Maria Lid6n, David Garcia-Dorado, Jaume Figueras, Juan Oliveras,
Anna Angles, Jasone Monasterio, J. Soler-Soler, Pierre Theroux. Hospital Vall
d'Hebron, Barcelona, Spain; Montreal Heart Institute, Montreal, Canada
Prompt inhibition of platelet aggregation is important in acute coronary syn-
drome and before an intervention procedure. To determine whether a single
low dose of iv aspirin inhibits platelet aggregation, twenty-seven healthy vol-
unteers (7 F and 20 Mj, mean age 43.5 years, were randomized double-blind
to a single iv low dose of aspirin OL-Iysine (L-ASA) equivalent to 2 mg!kg of
aspirin, high dose (H-ASA) equivalent to 10 mg!kg, or placebo (PI). Platelet ag-
gregation were performed before and 1 hand 24 h after drug administration,
in whole blood (WB) using electrical impedance and in platelet-rich plasma
(PRP) by optical light transmittance. Baseline WB platelet aggregation (Col 3
ILg/ml) was the same with L-ASA, H-ASA and PI (24 ± 5, 23 ± 3 and 24 ± 4rl
respectively) and decreased significantly more with L-ASA and H-ASA than
with PI after 1 h.(17± 6, 15± 7 and 21 ±5rl p < O.Ol)and 24h(17 ± 7, 16±
6 and 25 ± 4rl P < 0.01). Results in PRP were similar:
Inhibition of nitric oxide synthesis causes a decrease in basal diameter of dis-
tal epicardial coronary arteries in patients (pts) with normal coronary arteries
(NCA). The effects of inhibition of nitric oxide synthesis with NG-monomethyl-
L-arginine (LNMMA) in atheromatous coronary arteries was evaluated in 13
pts with chronic stable angina (aged 57 ± 7 years, 11 males) due to angio-
graphically documented coronary artery disease and in 8 pts (aged 50 ± 5
years, 4 males) with angiographically NCA. LNMMA was infused intracoro-
nary at 4,8 and 16/Lmol/min each for 4 minutes. In response to low LNMMA.
4lLmollmin, there was a significant (p < 0.05) reduction in luminal diameter
of both proximal (from 3.49 ± 0.28 to 3.35 ± 0.28 mm) and distal (from 1.33
± 0.07 to 1.23 ± 0.06 mm) segments in patients with NCA. In patients with
atheromatous arteries there was a reduction in diameter of the distal seg-
ments (from 1.44 ± 0.06 to 1.33 ± 0.07 mm) but no change occurred in the
proximal segments (from 2.95 ± 0.16to 2.89 ± 0.16 mm). In response to high
LNMMA. 16ILmol/min, there was a significant (p < 0.01) reduction in luminal
diameter of both proximallfrom 2.53 ± 0.27 to 2.33 ± 0.26 mm) and distal
(from 1.10 ± 0.06 to 0.99 ± 0.06 mm) segments in the pts with NCA. In the
pts with atheromatous arteries the distal segments decreased in diameter
(from 1.32 ± 0.07 to 1.17 ± 0.06 mm) but no change occurred in the proximal
segments (from 3.16 ± 0.12 to 3.08 ± 0.14 mm). The magnitude of the distal
vessel constriction was similar in both the patients with normal and in those
with atheromatous arteries (-9.6 ± 2.1 % and -10.9 ± 2.6% respectively, p
= NS). In conclusion in pts with chronic stable angina due to coronary artery
disease inhibition of basal nitric oxide synthesis causes distal coronary artery
vasoconstriction, but it has no effect on proximal segments.
1931-1121 A Low-dose Intravenous Aspirin, Bolus Injection,
Effectively Inhibits Platelet Aggregation
1931-1151 Phase I Studies on Inogatran, a New Selective
Thrombin Inhibitor
*p < 0.001 IANOVA test} respect to PI and the baseline values
No differences in response were observed between the two doses of aspirin
and no significant changes occurred between 1 and 24 hours in any group.
Effective inhibition of platelet aggregation is thus achieved within 1 hour
after the administration of low-dose 2 mg!kg of ivaspirin.
Ann-Catrine Teger-Nilsson, Ulf Eriksson, DaVid Gustafsson, Ruth Bylund,
Gunnar Fager, Peter Held. Astra Hassle AB, 5-431 83 M6lndal, Sweden
Inogatran is a new, synthetic, active site inhibitor of thrombin with a molecular
weight of 439 dalton. Inogatran (pINNI selectively, rapidly and competitively
binds thrombin with a Ki value of 15 nmol/l. In vitro it doubles the plasma
